Compare ASIX & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASIX | OCGN |
|---|---|---|
| Founded | 2016 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 527.0M | 570.5M |
| IPO Year | 2016 | 2014 |
| Metric | ASIX | OCGN |
|---|---|---|
| Price | $23.03 | $1.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $26.00 | $9.75 |
| AVG Volume (30 Days) | 450.0K | ★ 8.1M |
| Earning Date | 05-01-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.75% | N/A |
| EPS Growth | 11.11 | ★ 31.58 |
| EPS | ★ 1.80 | N/A |
| Revenue | ★ $1,684,625,000.00 | N/A |
| Revenue This Year | $4.19 | N/A |
| Revenue Next Year | $4.60 | $1,718.38 |
| P/E Ratio | $12.97 | ★ N/A |
| Revenue Growth | ★ 45.49 | N/A |
| 52 Week Low | $14.10 | $0.65 |
| 52 Week High | $25.94 | $2.73 |
| Indicator | ASIX | OCGN |
|---|---|---|
| Relative Strength Index (RSI) | 52.43 | 47.53 |
| Support Level | $20.28 | $1.64 |
| Resistance Level | $25.74 | $1.93 |
| Average True Range (ATR) | 0.92 | 0.10 |
| MACD | -0.30 | -0.02 |
| Stochastic Oscillator | 0.83 | 38.57 |
AdvanSix Inc is a diversified chemistry company playing a critical role in international supply chains, innovating and delivering essential products for customers across a wide variety of end markets and applications that touch people's lives, including building and construction, fertilizers, agrochemicals, plastics, solvents, packaging, paints, coatings, adhesives, and electronics. The company's key products include Nylon, Caprolactam, Plant Nutrients, and Chemical Intermediates. The majority of sales are from Plant Nutrients products. The company operates in the United States and internationally, with the majority of revenue coming from the United States.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").